Miromatrix Announces Participation in the 19th Annual Craig-Hallum Institutional Investor Conference
Miromatrix Medical Inc. (NASDAQ: MIRO) announced participation in the 19th Annual Craig-Hallum Institutional Investor Conference on June 1, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Miromatrix Medical Inc. (NASDAQ: MIRO) announced participation in the 19th Annual Craig-Hallum Institutional Investor Conference on June 1, 2022. This event will not feature a webcast. Miromatrix is focused on bioengineering fully transplantable organs, using its proprietary perfusion technology to address organ shortages, specifically targeting human livers and kidneys. The company aims to save and improve patients' lives through its innovative approach to organ development.
Positive
- Participation in a prominent investor conference may enhance visibility among institutional investors.
- Focus on bioengineering transplantable organs addresses a critical shortage, positioning the company as a pioneer in a growing market.
Negative
- None.
Details
News Market Reaction – MIRO
The recorded move for MIRO in the trading session of this news was -0.53%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EDEN PRAIRIE, Minn., May 25, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced that members of the management team will participate in the upcoming 19th Annual Craig-Hallum Institutional Investor Conference on June 1st, 2022. Due to the format of this event, no webcast will be available.
About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.
Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com
Media Contact:
press@miromatrix.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.